Batch 001 - Live Allocation

Next Release: Aug 2026

Vivre Labs

Institutional Longevity

Catalogue
Single-vial Blends · one injection
Clinical Details

- Peptides -

- Single-vial Blends -

- Goals -

- Clinical Reference -

- Guides -

- Integrity -

◇ Compound Reference

WEIGHT LOSS · ONCE WEEKLYFDA-ApprovedMost PrescribedPopular · Weight Management

Tirzepatide

Base Form · 10mg

Vial size

Status

FDA-Approved

Route

SubQ

Half-life

~5 days

Class

Synthetic dual agonist

MechanismGLP-1 / GIP Dual Agonist

Cohort203 active prescriptions

Educational reference only - not a prescription or dosing recommendation. Some compounds are investigational or used off-label; suitability, dose, and monitoring are determined by your supervising physician. See Informed Consent & Disclaimer.

V-Series Member

$130 USD/vial

À-la-carte: $145 USD/vial · Save 10%

Vials per allocation

Member total (1×)$130

À-la-carte total$145

Flat per-vial pricing. Quantity is allocated and dispensed within your physician-supervised protocol - not a direct sale.

What this is

Dual incretin receptor agonist driving glucose homeostasis and visceral adiposity reduction. Base Form ensures molecular identity to clinical trial specifications.

Base Form · 10mg per vial · dispensed after a physician review.

◇

Janoshik Verified

HPLC + MS purity, every batch

Independent third-party lab

⬡

COA Per Batch

Lot-level certificates published

Labeled vs actual mg disclosed

⊙

Protocol Reviewed

Used in V-Series clinical stacks

Phase 1 supervision onboarding

Used inV-Series

V-03

Metabolic - Weight & Blood Sugar

Popular · GLP-1 + Lean Mass

Tirzepatide · Weight loss · once weekly

◆ Certificate of Analysis · Tirzepatide

JANOSHIK ANALYTICALHPLC + MS · Independent third-party

Batch 001 · lot VL-TRZ-2026-07A

Every 100 units are drawn from one lot and tested once. The certificate below is the one that applies to this batch - when it closes, the next opens with a new lot and a new certificate.

DEMO

Lot · VL-TRZ-2026-05A

99.91%

Labeled

10 mg

Actual (HPLC)

10.68 mg

Method

HPLC + MS

Tested

May 10, 2026

Endotoxin

not tested for this lot

Heavy metals

not tested for this lot

◉

Clinical Overview

Tirzepatide

Tirzepatide is a 39-amino-acid synthetic peptide that functions as a dual GLP-1 and GIP receptor agonist. FDA-approved for type 2 diabetes and obesity (under brand names Mounjaro and Zepbound).

Demonstrates superior weight reduction vs. GLP-1 monotherapy in head-to-head trials.

✦

Dual Incretin Action

Activates GLP-1 and GIP receptors for appetite and glucose control.

❤

Insulin Sensitization

Improves insulin response and glucose handling.

◈

Appetite & Gastric Effects

Slows gastric emptying and reduces appetite signaling.

◈

Mechanism

How It Works

Simultaneous activation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Effects include insulin sensitization, gastric emptying delay, central appetite suppression, and improved beta-cell function.

⚐

Patient Education

Before & during use - what to know

Tirzepatide is an FDA-approved dual agonist (GLP-1 / GIP) - branded as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Among the most rigorously studied compounds Vivre carries, with Phase 3 head-to-head superiority over semaglutide (SURPASS-2) and ~22.5% mean weight reduction at 72 weeks at the 15mg dose (SURMOUNT-1). The strong evidence base does not eliminate the patient-education context below - titration, lifestyle foundation, and cycling considerations apply across the GLP-1 class.

↗TitrationStart low, observe four weeks per step

FDA-approved titration starts at 2.5mg weekly for the first 4 weeks, then escalates by 2.5mg every 4 weeks based on tolerability (5mg, 7.5mg, 10mg, 12.5mg, up to 15mg). **The 2.5mg starting dose is a tolerability dose, not a therapeutic dose** - and starting higher or skipping the 4-week observation window is the single most common driver of severe early-titration side effects in clinical practice and across patient communities. The 4-week observation window at each dose is the published trial protocol - not optional. The dose-limiting side effects - nausea, GI discomfort, fatigue, mild heart rate elevation - appear within this window and typically improve as the body adapts. Rapid escalation is the single most common reason patients discontinue. **Sensitivity-adapted starts:** patients with prior moderate-to-severe GLP-1 side effects, baseline body mass <55kg, known GI sensitivity, or age >65 with first-time GLP-1 exposure may start at 1.5mg or hold 2.5mg for 8 weeks before advancing - physician discretion. Maximum tolerated dose, not maximum approved dose, is the target.

♡Cardiovascular MonitoringMild resting HR elevation is expected

Tirzepatide elevates resting heart rate by approximately 2–3 BPM on average in trial data - milder than retatrutide but still a class effect of GLP-1 / GIP agonists. Track resting HR at baseline and through titration (a wearable is sufficient). The cardiovascular safety profile is well-characterised through Phase 3 trials; SURMOUNT and SURPASS programmes did not identify class-specific cardiovascular risk in approved-indication patients. Persistent symptoms (palpitations, chest discomfort) warrant pausing and contacting your physician.

Vivre recommends caution for patients with known arrhythmia, recent cardiac events, or untreated hypertension. In these cases, allocation is reviewed individually with cardiology input as appropriate.

◊Lifestyle FoundationSustained results require sustained habits

The strongest published evidence on tirzepatide discontinuation comes from SURMOUNT-4 - patients who stopped after 36 weeks of titration regained approximately half of their lost weight within the next 52 weeks. The drug is not the foundation; the foundation is the protocol. Sustainable outcomes require: a moderate caloric deficit (not extreme - the appetite suppression already produces a substantial deficit), **adequate protein (target 1.6–2.0 g/kg body weight daily during active weight loss to preserve lean mass; patients with very low baseline protein intake can begin at 1.25–1.5 g/kg as a floor and progress upward)**, micronutrient-dense food, resistance training at least 2× weekly, and adequate sleep. The drug makes the foundation easier to maintain - it does not replace it.

◇Digestion & HydrationGastric emptying slows - eat and drink accordingly

Tirzepatide delays gastric emptying - the satiety mechanism that drives the drug's effectiveness is the same mechanism that produces nausea and discomfort when meals are too large or too fatty. Practical consequence: smaller meals, eaten slowly, with attention to early-satiety signals. **A note on carbonated water:** despite community-practice mentions of carbonation easing fullness, current clinical guidance points the opposite direction - trapped CO2 from carbonation amplifies bloating, distension, and reflux when gastric emptying is already delayed. Standard physician advice is to avoid carbonated beverages during titration and at higher doses. Still water, ginger tea, peppermint tea, or warm water are the better choices. **Hydration pattern:** sip throughout the day rather than gulping at meals - fluid bolus while gastric emptying is delayed amplifies fullness and nausea. **Electrolyte awareness:** sodium, potassium, and magnesium loss accelerates when appetite suppression reduces food intake. Persistent fatigue, dizziness, or muscle cramps often resolve with light electrolyte supplementation - discuss with your physician.

❄Storage & StabilityVivre sizes vials to your titration window - not pharmaceutical-distribution convenience

Reconstituted peptides degrade over time. Industry-standard data for bacteriostatic-water reconstituted GLP-1 agonists places usable potency at approximately 4 weeks refrigerated, with measurable degradation accumulating beyond that - aggregation, oxidation, and conformational drift are the relevant pathways. Once you mix the vial, every additional day in solution is degradation, even at proper refrigeration. Vivre sizes tirzepatide vials at 10–20mg specifically to match a real titration or maintenance window of 2–4 weeks per vial, so the product you inject in week 3 is at near-peak potency rather than degraded by a long shelf life in solution. The trade-off is more frequent shipments and reconstitutions versus the 30–60mg variants some research vendors sell - but those larger vials only work at peak potency for the first 2–3 weeks of a longer consumption window, and dose-to-dose consistency drifts as the vial ages. Sizing matters for predictable response, especially during active titration.

Standard storage: keep lyophilized vials refrigerated 2–8°C (or room-temp short-term before reconstitution). After reconstitution, refrigerated 2–8°C only - never freeze, never expose to direct light, never leave at room temperature beyond brief warming for injection.

⊙CyclingVivre recommends 3 months on, 1 month off

Vivre recommends cycling tirzepatide on a 3-months-on, 1-month-off cadence under physician supervision. The reasoning: (a) extended continuous GLP-1 / GIP receptor activation may produce receptor downregulation over time, and a planned washout helps preserve responsiveness for subsequent on-cycles; (b) the long-term digestive-tract effects of years of continuous gastric-emptying delay are not fully characterised - even with tirzepatide's strong RCT base, post-marketing surveillance extends only a few years; (c) the off-month gives the body a recovery window, lets patients confirm lifestyle changes are sustaining benefit independent of the drug, and resets tolerance for the next on-cycle. Honest framing: Phase 3 trials (SURMOUNT, SURPASS) ran continuous dosing - cycling is not a clinical-trial-validated protocol but a mechanistically-reasoned physician practice. Patients with severe metabolic indications (uncontrolled T2DM, BMI driving immediate health risk) may have physician guidance to maintain continuous dosing instead.

The off-month is not a free pass - lifestyle foundation must continue. The cycling recommendation assumes those habits are in place. Cycling is also not appropriate for patients using tirzepatide for active glycemic control of type 2 diabetes - continuous coverage is the standard there.

The points above are educational context, not medical advice. Tirzepatide is FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Vivre supervises tirzepatide use with informed consent, baseline labs, and titration aligned with the approved Phase 3 protocol.

✚

Patient Bloodwork Guide

Bloodwork for Metabolic & Weight Protocols

GLP-1 class - Tirzepatide, Retatrutide, Semaglutide, Cagrilintide, V-03, V-M2

These protocols work on appetite, insulin sensitivity, and how your body stores fat. Monitoring tracks both the metabolic benefit and the things that change quickly during weight loss - blood sugar, lipids, and lean-mass markers.

Incremental approach. Doses are titrated upward slowly from a low starting point. Maintenance is typically a moderate dose - pushing higher rarely adds benefit and adds side effects. Monitoring guides where you settle.

Blood sugar & insulin

Fasting insulinTracks insulin sensitivity - usually the first thing to improve.

HbA1cYour 3-month average blood sugar.

Fasting glucoseRoutine blood-sugar tracking.

Heart & lipids

Full lipid panelLDL, HDL, triglycerides, ApoB - these shift meaningfully during weight loss.

Resting heart rate & BPSimple checks tracked through the protocol.

Muscle & body composition

IGF-1Helps your physician protect lean mass during rapid weight loss.

DEXA / body compositionConfirms you are losing fat, not muscle - the goal of pairing with resistance training.

Overall safety

CMP & liver enzymesKidney and liver function (AST/ALT), watched especially when compounds are combined.

ThyroidBaseline check, as thyroid influences metabolic rate.

When the tests happen

BaselineCMP, HbA1c, fasting insulin, full lipids, liver, thyroid, IGF-1, DEXA.

Weeks 4 / 8 / 12 / 16Weight, resting HR, BP, symptom check.

QuarterlyCMP, HbA1c, fasting insulin, lipids, liver, IGF-1, body composition.

Educational only - not medical advice or a dosing instruction. Your physician orders the tests, sets your dose, interprets results, and decides if a protocol is right for you. See the Informed Consent & Disclaimer for full terms.

◷

Lean-Mass Support During Weight Loss

A related option - discuss with your physician

Rapid GLP-1/GIP weight loss reduces fat and lean muscle. The foundation for preserving muscle is resistance training and adequate protein (roughly 1.2–1.6 g/kg/day for most people losing weight) - these do most of the work and come first.

As an adjunct, some patients discuss a GH-axis secretagogue protocol with their physician, on the rationale that supporting the growth-hormone / IGF-1 axis may help protect lean mass during a caloric deficit. This is mechanistically reasonable but not established by combination-outcome trials - there is no study showing it preserves more muscle than training and protein alone. Whether it is appropriate is a physician decision.

Educational only - not a recommendation to combine compounds or a dosing instruction. Any protocol decision is made by your supervising physician.

⊞

Technical Profile

Measurable Properties

Class	Dual receptor agonist - GLP-1 / GIP
Mechanism	Incretin-pathway activation; appetite and glycemic modulation - well-characterised
Terminal half-life	~5 days - supports once-weekly physician-directed dosing
Metabolism	Proteolytic cleavage; standard peptide elimination
Evidence base	Strong - approved-class agent with extensive clinical trial data
Regulatory status	Approved-class dual agonist; physician-supervised allocation, not for self-administration

Certificate of Analysis (per batch)

Analytical method: UHPLC-MS. Batch COA available on request - link to be populated per shipment.

COA link - pending per batch

Well-characterised, approved-class agent. Properties educational, not a dosing instruction; treatment is physician-determined.

Clinical Literature

Peer-Reviewed References

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022 · New England Journal of Medicine 2022;387:205–216

▾

Findings

Phase 3 RCT over 72 weeks. Mean weight reduction was 16.0%, 21.4%, and 22.5% at 5, 10, and 15 mg respectively, versus 2.4% on placebo. Body-composition analysis showed approximately 3-fold greater fat-mass reduction than lean-mass reduction. Three-year extension data have since shown durable maintenance of weight loss when therapy is continued under supervision.

View on publisher ↗

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)

Frías JP, Davies MJ, Rosenstock J, et al. · 2021 · New England Journal of Medicine 2021;385:503–515

▾

Findings

Head-to-head Phase 3 RCT in adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide produced superior reductions in HbA1c and body weight compared with semaglutide 1 mg at 40 weeks. Patients on tirzepatide 15 mg had approximately twice the weight loss of those on semaglutide 1 mg, with a comparable gastrointestinal adverse-event profile. First major head-to-head incretin-class trial.

View on publisher ↗

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5)

Aronne LJ, Horn DB, le Roux CW, et al. · 2025 · New England Journal of Medicine 2025;393:26–36

▾

Findings

Phase 3b open-label, controlled, head-to-head trial over 72 weeks in adults with obesity but without type 2 diabetes. Tirzepatide produced superior reductions in body weight and waist circumference versus semaglutide 2.4 mg (the approved obesity dose). Gastrointestinal adverse events leading to discontinuation occurred more often with semaglutide than tirzepatide. First direct comparative obesity trial between the two agents.

View on publisher ↗

Tirzepatide is an approved-class dual agonist with a substantial human evidence base spanning monotherapy efficacy (SURMOUNT-1), head-to-head superiority in type 2 diabetes (SURPASS-2), and head-to-head superiority in obesity (SURMOUNT-5). Use at Vivre is physician-supervised; suitability, dosing, and titration are determined in consultation, not by the patient.

◇

Clinical Applications

Indications

Type 2 diabetes management
Obesity / weight management
Metabolic syndrome
Component of metabolic-aesthetic protocols (V-03)

⊙

Pharmacokinetics

Half-Life & Duration of Action

Half-life is how long a compound stays at active plasma concentration in your body. Most peptides in this catalogue have short plasma half-lives - they clear from your bloodstream within hours, sometimes minutes. The long-half-life compounds in this catalogue are the approved-class incretins (Tirzepatide, Semaglutide, Retatrutide), which are designed for once-weekly dosing - that's the molecular engineering choice that makes weekly dosing work.

Plasma Half-Life

~5 days. Designed for once-weekly subcutaneous administration - the long half-life is a deliberate engineering property of the molecule, not an unintended persistence.

Why this matters for you

If you don't tolerate a compound or need to discontinue a protocol, short-half-life peptides are out of your bloodstream within hours - not days or weeks. That said, the biological effects they initiate (tissue repair signalling, mitochondrial signalling, gene expression changes) often persist longer than the peptide itself, through downstream cellular cascades. This is normal peptide pharmacology and is important context - the molecule clears fast, but the biology takes longer to wind down.

Evidence Base

FDA-approved with extensive Phase 3 trial data (SURPASS, SURMOUNT trials). Human clinical evidence is robust.

Dosing protocols, administration frequency, and titration schedules are physician-determined at consultation - not published on these public pages. Vivre maintains a separate internal clinical reference for treating physicians.

▣

Featured In

V-Series Protocols Including Tirzepatide

◎

Commonly Paired

Compounds Often Prescribed With Tirzepatide

Clinical co-allocation patterns observed in Vivre's allocation history. Pairings are not prescriptions - the physician determines suitability per patient at consultation.

Growth Hormone Secretagogue

Tesamorelin

GHRH Analog · 10mg

◆ lean-mass preservation

Tesamorelin is added during aggressive metabolic protocols to preserve visceral fat reduction and lean-mass profile (supported by NEJM evidence in lipodystrophy). This pairing appears in Vivre's V-03 protocol.

View Tesamorelin detail →

Cytoprotective Peptide

BPC-157

Base Form · 5mg

◆ GI tolerance

BPC-157 is co-allocated to support gastric and intestinal tolerance during incretin-class therapy, where GI side effects are common. Also part of V-03.

View BPC-157 detail →

READY TO PROCEED

Start with the Biological Audit

Tirzepatide is verified and lot-tested, dispensed following a Biological Audit. The Audit is complimentary for the Batch 001 cohort.

$130 USD/vial

Tirzepatide · Member rate